Vaibhav Agrawal, M.D., M.B.A.
- Hematology & Hematopoietic Cell Transplantation
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Hematology and Hematopoietic Cell Transplantation
- Post-transplant Relapse
- Graft-versus-host Disease
- Immunotherapy and Cellular Therapy
- Adolescent and Young Adult Oncology
- Cancer Survivorship
- Health Care Quality and Delivery
- Assistant Professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation
Location
Chicago Cancer Center
Zion, IL 60099
Duarte Cancer Center
Duarte, CA 91010
Education & Experience
2014, Masters of Jurisprudence (M.J.), Health Care Law, Loyola University Chicago School of Law, Chicago, IL
2013, Doctor of Medicine (M.D.), Chicago Medical School, Rosalind Franklin University of Medicine and Science North Chicago, IL
2011, Masters of Science Healthcare Administration (M.S.H.A.), College of Health Professions, Rosalind Franklin University of Medicine and Science, North Chicago, IL
2011, Masters of Business Administration (M.B.A.), Healthcare Management, Loyola University Quinlan School of Business, Chicago, IL
2021, Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford, CA
2020, Hematology-Oncology, Indiana University, Melvin and Bren Simon Cancer Center, Indianapolis, IN
2016-2017, Chief Resident, Internal Medicine-Pediatrics, Geisinger Medical Center, Danville, PA
2021-Present, Assistant Professor, Division of Leukemia, Department of
Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California
Awards & Memberships
Awards
2011, Beta Gamma Sigma
2006, Clinton E. Stryker Distinguished Service Award
2006, Leadership Academy Scholarship
2003, Phillip Danforth Armour Scholarship
2003, ABC-7 Los Angeles Cool Kid
Memberships
American Association for Physician Leadership
Society of Physician Entrepreneurs
American Society of Clinical Oncology
American Society of Hematology
American Society for Transplantation and Cellular Therapy
Publications
Pourhassan, H., Agrawal, V., Pullarkat, V., & Aldoss, I. (2023). Positioning blinatumomab in the frontline of adult B-cell acute lymphoblastic leukemia treatment. Frontiers in oncology, 13, 1237031. https://doi.org/10.3389/fonc.2023.1237031
Agrawal, V., & Aldoss, I. (2023). Searching for the optimal sequence of dual-targeted CAR T cells in relapsed/refractory acute lymphoblastic leukemia. Chinese clinical oncology, 12(4), 33. https://doi.org/10.21037/cco-23-31
Katiyar, P., Schwenck, J., Frauenfeld, L., Divine, M. R., Agrawal, V., Kohlhofer, U., Gatidis, S., Kontermann, R., Königsrainer, A., Quintanilla-Martinez, L., la Fougère, C., Schölkopf, B., Pichler, B. J., & Disselhorst, J. A. (2023). Quantification of intratumoural heterogeneity in mice and patients via machine-learning models trained on PET-MRI data. Nature biomedical engineering, 7(8), 1014–1027. https://doi.org/10.1038/s41551-023-01047-9
Yao, J. M., Otoukesh, S., Kim, H., Yang, D., Mokhtari, S., Samara, Y., Blackmon, A., Arslan, S., Agrawal, V., Pourhassan, H., Amanam, I., Ball, B., Koller, P., Salhotra, A., Becker, P., Curtin, P., Artz, A., Aldoss, I., Ali, H., Stewart, F., … Al Malki, M. M. (2023). Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis. Transplantation and cellular therapy, 29(8), 515.e1–515.e7. https://doi.org/10.1016/j.jtct.2023.05.008
Tamari, R., McLornan, D. P., Ahn, K. W., Estrada-Merly, N., Hernández-Boluda, J. C., Giralt, S., Palmer, J., Gale, R. P., DeFilipp, Z., Marks, D. I., van der Poel, M., Verdonck, L. F., Battiwalla, M., Diaz, M. A., Gupta, V., Ali, H., Litzow, M. R., Lazarus, H. M., Gergis, U., Bashey, A., … Saber, W. (2023). A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis. Blood advances, 7(15), 3993–4002. https://doi.org/10.1182/bloodadvances.2023009886
Aldoss, I., Afkhami, M., Yang, D., Gu, Z., Mokhtari, S., Shahani, S., Pourhassan, H., Agrawal, V., Koller, P., Arslan, S., Tomasian, V., Al Malki, M. M., Artz, A., Salhotra, A., Ali, H., Aribi, A., Sandhu, K. S., Ball, B., Otoukesh, S., Amanam, I., … Pullarkat, V. (2023). High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia-like fusions. American journal of hematology, 98(6), 848–856. https://doi.org/10.1002/ajh.26908
Agrawal, V., Pourhassan, H., Tsai, N. C., Ngo, D., Koller, P., Malki, M. M. A., Salhotra, A., Ali, H., Aribi, A., Sandhu, K. S., Arslan, S., Ball, B., Otoukesh, S., Amanam, I., Artz, A., Singh, D., Becker, P. S., Stewart, F. M., Smith, E. P., Curtin, P., … Aldoss, I. (2023). Post-Transplantation Sinusoidal Obstruction Syndrome in Adult Patients with B Cell Acute Lymphoblastic Leukemia Treated with Pretransplantation Inotuzumab. Transplantation and cellular therapy, 29(5), 314–320. https://doi.org/10.1016/j.jtct.2023.01.017
Agrawal, V., Salhotra, A., Song, J., Gu, Z., Stein, A. S., Marcucci, G., Forman, S. J., Pullarkat, V., & Aldoss, I. (2023). The feasibility of additional CD19-targeted cellular therapy in relapsed/refractory B-ALL with re-emergence of CD19 antigen after prior CD19-negative relapse. American journal of hematology, 98(2), E38–E40. https://doi.org/10.1002/ajh.26787
Feurstein, S., Trottier, A. M., Estrada-Merly, N., Pozsgai, M., McNeely, K., Drazer, M. W., Ruhle, B., Sadera, K., Koppayi, A. L., Scott, B. L., Oran, B., Nishihori, T., Agrawal, V., Saad, A., Lindsley, R. C., Nakamura, R., Kim, S., Hu, Z., Sobecks, R., Spellman, S., … Godley, L. A. (2022). Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages. Blood, 140(24), 2533–2548. https://doi.org/10.1182/blood.2022015790
Phelan, R., Im, A., Hunter, R. L., Inamoto, Y., Lupo-Stanghellini, M. T., Rovo, A., Badawy, S. M., Burns, L., Eissa, H., Murthy, H. S., Prasad, P., Sharma, A., Suelzer, E., Agrawal, V., Aljurf, M., Baker, K., Basak, G. W., Buchbinder, D., DeFilipp, Z., Grkovic, L. D., … Tichelli, A. (2022). Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Bone marrow transplantation, 57(7), 1150–1163. https://doi.org/10.1038/s41409-022-01591-z
- Methany L, Callander NS, Hall AC, Zhang MJ, Bo-Subait K, Wang HL, Agrawal V, et al. Allogeneic transplantation to treat therapy-related myelodysplastic syndrome and acute myelogenous leukemia in adults. Transplant Cell Ther. 2021 Aug; S2666-6367(21)01146-5.doi: 10.1016/j.jtct.2021.08.010.
- Agrawal V, Abonour R, Abu Zaid M, Althouse SK, et al. Survival outcomes and toxicity in patients 40 years old or older with relapsed metastatic germ cell tumors treated with high-dose chemotherapy and peripheral blood stem cell transplantation. Cancer. 2021 Oct; 127(20):3751-3760.
- Agrawal V, Ranganath P, Ervin KD, et al. Effect of Sirolimus Levels Between Days 11 and 20 After Allogeneic Stem Cell Transplantation on the Risk of Hepatic Sinusoidal Obstruction Syndrome. Bone Marrow Transplant. 2021 Jan;56(1):121-128.
- Munshi PN, Vesole D, Jurczysyn A, Zaucha JM, St. Martin A, Davilla O, Agrawal V, et al. Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. Cancer. 2020 Dec; 126(23):5077-5087.
- Im A, Rashidi A, Wang T, Hemmer M, MacMillan ML, Pidala L, Jagasia M, Pavletic S, Majhail NS, Weisdorf D, Abdel-Azim H, Agrawal V, et al. Risk factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation using Post-Transplantation Cyclophosphamide. Biol Blood Marrow Transplant. 2020 Aug; 26(8):1459-1468.
- Christian S, Arain S, Patel P, Khan I, Calip GS, Agrawal V, et al. A multi-institution comparison of mitoxantrone, etoposide, and cytarabine vs. high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia. Am. J. Hematol. 2020 Aug; 95(8):937-943.
- Zhou Z, Nath R, Cerny J, Wang HL, Zhang MJ, Abdel-Azim H, Agrawal V, et al. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Adv. 2020 Jul; 4(13):3180-3190.
- Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Azim H, Agrawal V, et al. Composite GRFS and CRFS Outcomes after Adult Alternative Donor HCT. J. Clin. Oncol. 2020 Jun; 38(18):2062-2076.
- Agrawal V, Brinda BJ, Farag SS. Histoplasma capsulatum infection in an allogeneic hematopoietic stem cell transplant receiving voriconazole prophylaxis. Case Rep. Hematol. 2020; 2020:8124137.
- Agrawal V, Gbolahan OB, Stahl M, Zeidan AM, et al. Vaccine and Cell Based Therapeutics in Acute Myeloid Leukemia. Curr. Cancer Drug Targets. 2020 May; 20(7):473-489.
- Agrawal V, Dinh PC Jr., Fung C, Monahan PO, et al. Adverse Health Outcomes among US Testicular Cancer Survivors after Cisplatin-Based Surgical Management. JNCI Cancer Spectr. 2019 Oct;4(2):pkz079.
- Agrawal V, Adra N. Salvage therapy for relapsed testicular cancer: a need for consensus. Future Oncol. 2019 Dec; 15(34):3881-3884.
- Saad A, Lamb L, Wang T, Hemmer MT, Spellman S, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Agrawal V, et al. Impact of T cell dose on T cell-replete HLA matched allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2019 Sep; 25(9):1875-1883.
- Kilari D, D’Souza A, Fraser R, Qayed M, Davilla O, Agrawal V, et al. Autologous Transplantation for Male Germ Cell Tumors: Improved Outcomes over 3 decades. Biol Blood Marrow Transplant. 2019 Jun; 25(6):1099-1106.
- Parikh SH, Satwani P, Ahn KW, Sahr NA, Fretham C, Abraham AA, Agrawal V, et al. Survival trends in infants undergoing allogeneic hematopoietic cell transplant. JAMA Pediatr. 2019 May; 173(5):e190081.
- Inamoto Y, Petricek I, Burns L, Chhabra S, DeFilipp Z, Hematti P, Rovo A, Schears R, Shaha A, Agrawal V, et al. Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the late effects and quality of life working committee of the CIBMTR and transplant complications working party of the EBMT. Bone Marrow Transplant. 2019 May; 54(5):648-661.
- Salwei ME, Carayon P, Hundt AS, Hoonaker P, Agrawal V, et al. Role network measures to assess healthcare team adaptation to complex situations: the case of venous thromboembolism prophylaxis. Ergonomics. 2019 Apr. 62(7): 864-879.
- Brunstein CG, Pasquini MC, Kim S, Fei M, Adekola K, Ahmed I, Aljurf M, Agrawal V, et al. Effect of conditioning regimen dose reduction in obese patients undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019 Mar; 25(3):480-487.
- Scott EC, Hari P, Kumar S, Fraser R, Davilla O, S N, Gale RP, Diaz MA, Agrawal V, et al. Staging systems for newly diagnosed myeloma patients undergoing autologous hematopoietic cell transplantation: the revised international staging system shows the most differentiation between groups. Biol Blood Marrow Transplant. 2018 Dec; 24(12):2443-2449.